• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.42% Nasdaq Up0.16%

    More On CYCCP



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    • Income Statement
    • Balance Sheet
    • Cash Flow

    Cyclacel Pharmaceuticals, Inc. (CYCCP)

    6.18 0.00(0.00%) Dec 18
    Add to Portfolio
    ProfileGet Profile for:
    Cyclacel Pharmaceuticals, Inc.
    200 Connell Drive
    Suite 1500
    Berkeley Heights, NJ 07922
    United States - Map
    Phone: 908-517-7330
    Fax: 866-271-3466
    Website: http://www.cyclacel.com

    Index Membership:N/A
    Full Time Employees:18

    Business Summary 

    Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The company’s oncology development programs include sapacitabine, an orally-available nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-available 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its other oncology development programs comprise CYC065, an orally-available 2nd generation CDK-2, -5, -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; and Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer. The company’s non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cyclacel Pharmaceuticals, Inc.

    Key Executives 
    Mr. Spiro Rombotis , 55
    Chief Exec. Officer, Pres and Exec. Director
    Mr. Paul McBarron , 53
    Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Exec. VP of Fin. & Admin., Sec. and Exec. Director
    Dr. Judy H. Chiao M.D., 54
    Chief Medical Officer and VP of Clinical Devel. & Regulatory Affairs
    Prof. David Glover Ph.D., FRS FRSE, 66
    Chief Scientist
    Dr. Susan Davis Ph.D.,
    Director of Bus. Devel.
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.